Changes to OTC cannabis sales just around the corner
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The Therapeutic Goods Administration (TGA) will shortly bring down its final decision regarding a major regulatory change in the distribution of cannabidiol (CBD) products in Australia.
The final decision is expected to be delivered in late December 2020, following on from the interim decision made in September.
The changes recommend that CBD products be down scheduled from schedule 4 and classified as schedule 3 medicines in Australia, which would allow Australian consumers to purchase CBD products over-the-counter (OTC) through pharmacies without the requirement of a prescription.
Read: Creso Pharma to benefit from OTC cannabis sales in Australia
It has been a slow but welcome move to get to this point. It wasn’t until 2016 that Australia legally recognised the difference between marijuana and hemp. Before that , cannabis products were classified as Schedule (S8) Drugs and were strictly regulated and deemed poisonous.
Following that, the TGA lifted the ban on hemp extracts.
It did so under the Australian medical cannabis program, with the downregulation leading to CBD oil being knocked down to a Schedule 4 (S4) classification.
With this new legislature, December’s changes will be welcome but strict.
CBD content must be at 98% or less, with the remaining 2% allowed to be any of the other 100+ phytocannabinoids found in hemp.
The TGA’s cautious approach is due to its belief that there are too few studies on each individual phytocannabinoid other than CBD and THC to deem these others safe or effective for medical treatment.
However, the decision regarding amendments to down schedule cannabidiol (CBD) products to schedule 3 medicine would allow Australian consumers to purchase CBD products following consultation with a pharmacist without the need for a prescription.
This is a major move forward.
Once the announcement is made official, a doctor when writing a prescription will be required to fill out a Special Access Scheme (SAS) – an official petition to the TGA to allow patients to access CBD oil under the Australian medical cannabis program.
At the moment, doctors can only prescribe approved items by the Australian Register of Therapeutic Goods (ARTG).
Creso Pharma ready to help make a difference
For Creso Pharma (ASX:CPH), the potential down scheduling of CBD products in Australia could unlock a major market for its CBD and hemp products.
It is estimated that the local market is currently at over $200M per annum and growing.
CPH develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.
It uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It also has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.
“The potential down scheduling of CBD is a major development for the broader market and provides Creso Pharma with a number of opportunities and potential new sales channels,” Non-Executive Chairman Adam Blumenthal said.
“Australia has always been considered an important market in our growth strategy. Ahead of the TGA’s final decision, the Board and management have been exploring initiatives which will allow us to capture a large market share in Australia and unlock value for our shareholders.
“The Company remains well capitalised and looks forward to providing ongoing updates on progress.”
CPH already has products available on the Australianb market.
Its cannaQIX® 50 is currently being sold in Australia as a medicinal cannabis product under the ‘LozaCan’ brand via distribution partner ‘Burleigh Heads Cannabis’ (BHC).
Creso has also developed a wide range of CBD and hemp-oil products under the cannaQIX® brand, using its proprietary and innovative delivery technology which it expects to sell in Australia following any favourable decision.
The cannaQIX® range is manufactured under Good Manufacturing Practice standards and provides consumers with a standardised formulation and precise dosage measurement.
tagsMEDICAL CANNABIS CANNABIS STOCKS THERAPEUTIC GOODS ADMINISTRATION TGA HEMP CANNABIDIOL CBD PRODUCTS
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.